Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin‐Dependent Kinase 4/6 Inhibitor Combination Therapy

• Published in: Hepatology (Baltimore, Md.) Vol. 74; no. 4; pp. 1971 - 1993
• Main Authors: Sheng, Jindan, Kohno, Susumu, Okada, Nobuhiro, Okahashi, Nobuyuki, Teranishi, Kana, Matsuda, Fumio, Shimizu, Hiroshi, Linn, Paing, Nagatani, Naoko, Yamamura, Minako, Harada, Kenichi, Horike, Shin‐ichi, Inoue, Hiroshi, Yano, Seiji, Kumar, Sharad, Kitajima, Shunsuke, Ajioka, Itsuki, Takahashi, Chiaki
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2021
• Subjects: AKT protein; Aminopyridines - pharmacology; Aminopyridines - therapeutic use; Animals; Antitumor activity; Apoptosis; Benzimidazoles - pharmacology; Benzimidazoles - therapeutic use; Breast cancer; Cancer; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - genetics; Cell cycle; Cell Proliferation - drug effects; Cell Proliferation - genetics; Cell Survival - drug effects; Clinical trials; Combination therapy; Cyclin-dependent kinase 4; Cyclin-Dependent Kinase 4 - antagonists & inhibitors; Cyclin-Dependent Kinase 6 - antagonists & inhibitors; Enzyme inhibitors; Hep G2 Cells; Hepatocellular carcinoma; Hepatocytes; Hepatology; Humans; IKK protein; Immunogenicity; In Vitro Techniques; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - genetics; Liver Neoplasms, Experimental - drug therapy; Liver Neoplasms, Experimental - genetics; Malignancy; Mice; Neoplasm Transplantation; Phosphorylation; Piperazines - pharmacology; Piperazines - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Purines - pharmacology; Purines - therapeutic use; Pyridines - pharmacology; Pyridines - therapeutic use; Retina; Retinoblastoma; Retinoblastoma Protein; Sarcoma; Senescence; Solid tumors; Tumor cell lines; Tumor Suppressor Protein p53 - genetics; Tumors; Xenopus Proteins

Background and Aims Synthetic cyclin‐dependent kinase (CDK) 4/6 inhibitors exert antitumor effects by forcing RB1 in unphosphorylated status, causing not only cell cycle arrest but also cellular senescence, apoptosis, and increased immunogenicity. These agents currently have an indication in advance...